Posts tagged price target
RBC cuts TSO3 to sector perform; PT to $2 from $4.25

RBC Dominion Securities downgraded TSO3 (TSX:TOS) to “sector perform” from “outperform” and slashed its price target to $2 from $4.25 after the company entered into a new co-distribution agreement with Getinge to sell the VP4 sterilizer directly into the U.S. and Canadian markets. The stock closed at $1.80 on Jan. 25.

Read More
Ladenburg starts Flex Pharma at buy; PT $12

Ladenburg Thalmann initiated coverage of Flex Pharma (NASDAQ:FLKS) with a “buy” rating and $12 price target. The stock closed at $4.02 on Jan. 24.

Read More
Maxim starts Immune Pharma at buy; PT $3

Maxim Group launched coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $3 price target. The stock closed at 57 cents on Jan. 4.

Read More
Ladenburg starts UroGen Pharma at buy; PT $50

Ladenburg Thalmann initiated coverage of UroGen Pharma (NASDAQ:URGN) with a “buy” rating and $50 price target. The stock closed at $37.21 on Dec. 29.

Read More